ESR1 and breast cancer: Moreover, a recent report describes the ability of cardiac glycosides Ouabain and Digoxin to degrade ERα, potentially via activation of the proteasomal system, with subsequent inhibition of estrogen signaling, cell cycle blockade and apoptosis of primary and metastatic breast cancer cells [106].